Top

Osteoporosis International

Published in:

01-09-2020 | Bisphosphonate | Original Article

Effects of anti-resorptive drugs on implant survival and peri-implantitis in patients with existing osseointegrated dental implants: a retrospective cohort study

Authors: J.Y. Kim, H. Choi, J.H. Park, H.D. Jung, Y.S. Jung

Published in: Osteoporosis International | Issue 9/2020

Abstract

Summary

The effect of anti-resorptive drug (ARD) usage among patients with successful dental implant osseointegration is controversial. This study showed an increased risk of implant failure in ARD users. Risk factors included pre-existing marginal bone loss, overdenture, diabetes, and a short interval between implant placement and ARD administration.

Introduction

This retrospective study aimed to determine whether anti-resorptive drug (ARD) usage increased risk of implant failure among patients with successful implant osseointegration. Additionally, the study investigated risk factors that affected implant survival rate in ARD users.

Methods

Eighty ARD users with 344 implants who had more than 12 months of follow-up from the initiation of ARD treatment during the period between 2008 and 2017 were included, along with 80 non-ARD users from the same period. The primary outcome was dental implant survival. Kaplan–Meier survival curves and Cox proportional hazard models were used for survival analysis.

Results

Average follow-up was 85.3 months. Implant survival rates were 89.83% in ARD users and 96.03% in non-ARD users. In the univariate Cox proportional hazard model, risk of implant failure was significantly higher in patients with pre-existing marginal bone loss (MBL), diabetes, and concurrent bone augmentation. However, risk of implant failure was significantly lower when the interval between implant placement and ARD administration was < 36 months. Compared with overdenture, single crown and fixed splinted users had lower risk of implant failure. In multivariate analysis, variables including pre-existing MBL, diabetes, < 36-month interval between implant placement and ARD treatment, and usage of fixed splinted prosthesis were significantly associated with increased risk of implant failure.

Conclusions

ARD administration after implant osseointegration was correlated with a reduced implant survival rate. Pre-existing MBL, diabetes, type of final prosthesis, and the interval between implant placement and initiation of ARD administration influenced risk of implant failure.

Available only for authorised users

Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677–692. https://doi.org/10.1016/j.bone.2010.11.020CrossRefPubMed

Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P (2003) Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 37(4):225–238PubMed

Reginster JY, Neuprez A, Beaudart C, Lecart MP, Sarlet N, Bernard D, Disteche S, Bruyere O (2014) Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis. Drugs Aging 31(6):413–424. https://doi.org/10.1007/s40266-014-0179-zCrossRefPubMedPubMedCentral

Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, le Bailly de Tilleghem C, Dasilva C, Rosenberg E, Leung A (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27(11):2251–2258. https://doi.org/10.1002/jbmr.1695CrossRefPubMed

Liu J, Huang W, Zhou R, Jia S, Tang W, Luo Y, Zhang J (2015) Bisphosphonates in the treatment of patients with metastatic breast, lung, and prostate cancer: a meta-analysis. Medicine (Baltimore) 94(46):e2014. https://doi.org/10.1097/md.0000000000002014CrossRef

Polyzos SA, Anastasilakis AD, Makras P, Terpos E (2011) Paget’s disease of bone and calcium homeostasis: focus on bisphosphonate treatment. Exp Clin Endocrinol Diabetes 119(9):519–524. https://doi.org/10.1055/s-0031-1284365CrossRefPubMed

Vescovi P (2012) Bisphosphonates and osteonecrosis: an open matter. Clin Cases Miner Bone Metab 9(3):142–144PubMedPubMedCentral

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72(10):1938–1956. https://doi.org/10.1016/j.joms.2014.04.031CrossRefPubMed

Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S (2007) Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18(10):1363–1370. https://doi.org/10.1007/s00198-007-0384-2CrossRefPubMed

10.

Brooks JK, Gilson AJ, Sindler AJ, Ashman SG, Schwartz KG, Nikitakis NG (2007) Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103(6):780–786. https://doi.org/10.1016/j.tripleo.2006.10.010CrossRefPubMed

11.

Wang HL, Weber D, McCauley LK (2007) Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol 78(3):584–594. https://doi.org/10.1902/jop.2007.060239CrossRefPubMed

12.

Bedogni A, Bettini G, Totola A, Saia G, Nocini PF (2010) Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review. J Oral Maxillofac Surg 68(7):1662–1666. https://doi.org/10.1016/j.joms.2010.02.037CrossRefPubMed

13.

Park W, Kim NK, Kim MY, Rhee YM, Kim HJ (2010) Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporos Int 21(3):527–533. https://doi.org/10.1007/s00198-009-0973-3CrossRefPubMed

14.

Narongroeknawin P, Danila MI, Humphreys LG Jr, Barasch A, Curtis JR (2010) Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist 30(2):77–82. https://doi.org/10.1111/j.1754-4505.2009.00128.xCrossRefPubMedPubMedCentral

15.

Giovannacci I, Meleti M, Manfredi M, Mortellaro C, Greco Lucchina A, Bonanini M, Vescovi P (2016) Medication-related osteonecrosis of the jaw around dental implants: implant surgery-triggered or implant presence-triggered osteonecrosis? J Craniofac Surg 27(3):697–701. https://doi.org/10.1097/scs.0000000000002564CrossRefPubMed

16.

Tam Y, Kar K, Nowzari H, Cha HS, Ahn KM (2014) Osteonecrosis of the jaw after implant surgery in patients treated with bisphosphonates—a presentation of six consecutive cases. Clin Implant Dent Relat Res 16(5):751–761. https://doi.org/10.1111/cid.12048CrossRefPubMed

17.

Jacobsen C, Metzler P, Rossle M, Obwegeser J, Zemann W, Gratz KW (2013) Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clin Oral Investig 17(1):167–175. https://doi.org/10.1007/s00784-012-0708-2CrossRefPubMed

18.

Lopez-Cedrun JL, Sanroman JF, Garcia A, Penarrocha M, Feijoo JF, Limeres J, Diz P (2013) Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series. Br J Oral Maxillofac Surg 51(8):874–879. https://doi.org/10.1016/j.bjoms.2013.06.011CrossRefPubMed

19.

Yip JK, Borrell LN, Cho SC, Francisco H, Tarnow DP (2012) Association between oral bisphosphonate use and dental implant failure among middle-aged women. J Clin Periodontol 39(4):408–414. https://doi.org/10.1111/j.1600-051X.2012.01854.xCrossRefPubMed

20.

Gupta R (2012) Early dental implant failure in patient associated with oral bisphosphonates. Indian J Dent Res 23(2):298. https://doi.org/10.4103/0970-9290.100471CrossRefPubMed

21.

Kasai T, Pogrel MA, Hossaini M (2009) The prognosis for dental implants placed in patients taking oral bisphosphonates. J Calif Dent Assoc 37(1):39–42PubMed

22.

Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schiodt M, Klinge B (2018) The effect of antiresorptive drugs on implant therapy: systematic review and meta-analysis. Clin Oral Implants Res 29(Suppl 18):54–92. https://doi.org/10.1111/clr.13282CrossRefPubMed

23.

Chappuis V, Avila-Ortiz G, Araujo MG, Monje A (2018) Medication-related dental implant failure: systematic review and meta-analysis. Clin Oral Implants Res 29(Suppl 16):55–68. https://doi.org/10.1111/clr.13137CrossRefPubMed

24.

Pogrel MA, Ruggiero SL (2018) Previously successful dental implants can fail when patients commence anti-resorptive therapy-a case series. Int J Oral Maxillofac Surg 47(2):220–222. https://doi.org/10.1016/j.ijom.2017.07.012CrossRefPubMed

25.

De Angelis F, Papi P, Mencio F, Rosella D, Di Carlo S, Pompa G (2017) Implant survival and success rates in patients with risk factors: results from a long-term retrospective study with a 10 to 18 years follow-up. Eur Rev Med Pharmacol Sci 21(3):433–437PubMed

26.

Tonetti M, Palmer R (2012) Clinical research in implant dentistry: study design, reporting and outcome measurements: consensus report of Working Group 2 of the VIII European Workshop on Periodontology. J Clin Periodontol 39(Suppl 12):73–80. https://doi.org/10.1111/j.1600-051X.2011.01843.xCrossRefPubMed

27.

Insua A, Monje A, Wang HL, Miron RJ (2017) Basis of bone metabolism around dental implants during osseointegration and peri-implant bone loss. J Biomed Mater Res A 105(7):2075–2089. https://doi.org/10.1002/jbm.a.36060CrossRefPubMed

28.

Messer JG, Jiron JM, Mendieta Calle JL et al (2019) Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis. Oral Dis. https://doi.org/10.1111/odi.13052

29.

Zahid TM, Wang BY, Cohen RE (2011) Influence of bisphosphonates on alveolar bone loss around osseointegrated implants. J Oral Implantol 37(3):335–346. https://doi.org/10.1563/aaid-joi-d-09-00114CrossRefPubMed

30.

Jeffcoat MK (2006) Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 21(3):349–353PubMed

31.

Grant BT, Amenedo C, Freeman K, Kraut RA (2008) Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 66(2):223–230. https://doi.org/10.1016/j.joms.2007.09.019CrossRefPubMed

32.

Bell BM, Bell RE (2008) Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg 66(5):1022–1024. https://doi.org/10.1016/j.joms.2007.12.040CrossRefPubMed

33.

Goss A, Bartold M, Sambrook P, Hawker P (2010) The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series. J Oral Maxillofac Surg 68(2):337–343. https://doi.org/10.1016/j.joms.2009.09.037CrossRefPubMed

34.

Shabestari GO, Shayesteh YS, Khojasteh A, Alikhasi M, Moslemi N, Aminian A, Masaeli R, Eslami B, Treister NS (2010) Implant placement in patients with oral bisphosphonate therapy: a case series. Clin Implant Dent Relat Res 12(3):175–180. https://doi.org/10.1111/j.1708-8208.2009.00150.xCrossRefPubMed

35.

Koka S, Babu NM, Norell A (2010) Survival of dental implants in post-menopausal bisphosphonate users. J Prosthodont Res 54(3):108–111. https://doi.org/10.1016/j.jpor.2010.04.002CrossRefPubMed

36.

Memon S, Weltman RL, Katancik JA (2012) Oral bisphosphonates: early endosseous dental implant success and crestal bone changes. A retrospective study. Int J Oral Maxillofac Implants 27(5):1216–1222PubMed

37.

Starck WJ, Epker BN (1995) Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 10(1):74–78PubMed

38.

Aljohani S, Fliefel R, Ihbe J, Kuhnisch J, Ehrenfeld M, Otto S (2017) What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review. J Craniomaxillofac Surg 45(9):1493–1502. https://doi.org/10.1016/j.jcms.2017.05.028CrossRefPubMed

39.

Ata-Ali J, Ata-Ali F, Penarrocha-Oltra D, Galindo-Moreno P (2016) What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res 27(2):e38–e46. https://doi.org/10.1111/clr.12526CrossRefPubMed

40.

Walter C, Al-Nawas B, Wolff T, Schiegnitz E, Grotz KA (2016) Dental implants in patients treated with antiresorptive medication—a systematic literature review. Int J Implant Dent 2(1):9. https://doi.org/10.1186/s40729-016-0041-7CrossRefPubMedPubMedCentral

41.

Monje A, Catena A, Borgnakke WS (2017) Association between diabetes mellitus/hyperglycaemia and peri-implant diseases: systematic review and meta-analysis. J Clin Periodontol 44(6):636–648. https://doi.org/10.1111/jcpe.12724CrossRefPubMed

Title: Effects of anti-resorptive drugs on implant survival and peri-implantitis in patients with existing osseointegrated dental implants: a retrospective cohort study
Authors: J.Y. Kim
H. Choi
J.H. Park
H.D. Jung
Y.S. Jung
Publication date: 01-09-2020
Publisher: Springer London
Keywords: Bisphosphonate
Osteoporosis
Osteoporosis
Published in: Osteoporosis International / Issue 9/2020
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-019-05257-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effects of anti-resorptive drugs on implant survival and peri-implantitis in patients with existing osseointegrated dental implants: a retrospective cohort study

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2020

Teriparatide improves microarchitectural characteristics of peri-implant bone in orchiectomized rats

Guidelines for the assessment of bone density and microarchitecture in vivo using high-resolution peripheral quantitative computed tomography

Identifying and managing osteoporosis before and after COVID-19: rise of the remote consultation?

Bone densitometry worldwide: a global survey by the ISCD and IOF

Pleiotropic loci underlying bone mineral density and bone size identified by a bivariate genome-wide association analysis

Vertebral fracture: clinical presentation and severity are linked to fracture risk factors